Search
Kindly MD Ord Shs
NAKAAdd to Watchlist
10.050USD
+0.880+9.60%
Close 09-18 16:00（ET）
179.67MMarket Cap
LossP/E TTM
Kindly MD Ord Shs (NAKA) Stock Price Target & Forecast
Analyst Rating
Based on 2 analysts
Buy
0 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
1.250USD+203.25%
NAKA Analyst Recommendation Trends
In the current month, NAKA has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NAKA average Analyst price target in the last month is 1.250.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
2
2
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
1
0
0
0
0
NAKA Analyst Rating for Peer Comparison
Updated: Sep 21, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
CVS Health Corp
CVS
7
18
4
0
0
29
HCA Healthcare Inc
HCA
5
9
11
1
0
26
Teladoc Health Inc
TDOC
2
4
19
0
0
25
Natera Inc
NTRA
10
11
3
0
0
24
Tenet Healthcare Corp
THC
5
14
4
0
0
23
Universal Health Services Inc
UHS
2
4
15
1
0
22
Labcorp Holdings Inc
LH
7
9
4
0
0
20
Brightspring Health Services Inc
BTSG
7
12
0
0
0
19
Quest Diagnostics Inc
DGX
5
5
9
0
0
19
Privia Health Group Inc
PRVA
6
12
1
0
0
19
Financial Forecasting
Based on analysts' estimates, NAKA EPS is projected to reach 0.000 in FY2026Q3, following reported EPS of -6649.850 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
Forecast
-0.01
0.01
--
--
Actual
0.19
-15.01
-6.65K
--
Surprise
+3822.20%
-150164.00%
--
--
FAQs
What is Kindly MD Ord Shs's expected revenue for the next quarter?
Kindly MD Ord Shs's expected revenue is 16.89M.
What is Kindly MD Ord Shs's price target?
Analysts forecast that Kindly MD Ord Shs's price target is USD 1.25, with the highest forecast at USD 1.50 and the lowest forecast at USD 1.00.
What is the analyst rating for Kindly MD Ord Shs?
Based on the ratings of Kindly MD Ord Shs's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.